MedTrace Logo

A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients

NCT00734032 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2018-01-12

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to examine the effects of SB-480848 on plasma lipoprotein associated phospholipase A2 (Lp-PLA2) activity in dyslipidemic patients during a 4-week treatment with SB-480848.

Conditions

Interventions

DRUG

SB480848 40mg EC Tablet

1 tablet once a day

DRUG

SB480848 80mg EC Tablet

1 tablet once a day

DRUG

SB480848 160mg EC Tablet

1 tablet once a day

DRUG

SB480848 Placebo Tablet

1 tablet once a day

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-26
Primary Completion
2009-01-16
Completion
2009-01-16

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00734032 on ClinicalTrials.gov